{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:18:10Z","timestamp":1761560290153,"version":"build-2065373602"},"reference-count":43,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,4,4]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumour activity of AMG 404, a fully human IgG1 monoclonal antibody targeting programmed cell death-1, in patients with advanced solid tumours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>First-in-human phase I study comprising eight dose expansion cohorts, including cohorts with microsatellite instability-high (MSI-H) tumours and non-small cell lung cancer with high programmed death-ligand 1 expression (NSCLC\/PDL1-H, tumour proportion score \u226550%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Conducted across 28 global sites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>This study enrolled adult patients with histologically or cytologically confirmed metastatic or locally advanced solid tumours not amenable to curative treatment with surgery or radiation. The inclusion criteria included a life expectancy of &gt;3 months, \u22651 measurable or evaluable lesion per modified Response Evaluation Criteria in Solid Tumours (RECIST) V.1.1, an Eastern Cooperative Oncology Group performance status of \u22642 and adequate haematological, renal and hepatic function. Patients with prior treatment with checkpoint inhibitors, primary brain tumour or untreated or symptomatic brain metastases and leptomeningeal disease and history of other malignancy within the past 2 years were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>The planned doses were 240 mg, 480 mg and 1050 mg of AMG 404 administered every 4 weeks (Q4W).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Primary endpoints were dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, changes in vital signs and clinical laboratory tests. Secondary endpoints included PK parameters, incidence of antidrug (AMG 404) antibodies and antitumour activity assessed per modified RECIST V.1.1 (objective response, duration of response, progression-free survival (PFS), disease control and duration of stable disease).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 171 patients were enrolled; 168 were treated. Median (range) follow-up was 36.3 weeks (1.6\u2013137.1). No DLTs were observed. Grade 3 and serious treatment-related adverse events occurred in 16 (9.5%) and 12 (7.1%) patients, respectively. The 480 mg Q4W dose was selected as the recommended phase II dose. AMG 404 serum exposure increased approximately dose proportionally. The objective response rate (80% CI) was 19.6% (15.7\u201324.1) for the overall population and 36.6% (26.4\u201347.8) and 30.8% (14.2\u2013\u200d52.3) for cohorts with MSI-H tumours (n=41) and NSCLC\/PDL1-H (n=13), respectively. The overall disease control rate (80% CI) was 54.8% (49.5\u201359.9). The median (80% CI) PFS was 3.7 (3.5\u20134.5) months for the overall population and 14.8 (9.0\u2013not estimable) and 4.4 (2.2\u20139.7) months for cohorts with MSI-H tumours and NSCLC\/PDL1-H, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AMG 404 monotherapy was tolerable at the tested doses, with encouraging antitumour activity observed across tumour types.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03853109\">NCT03853109<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-088578","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T08:04:57Z","timestamp":1746173097000},"page":"e088578","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03853109","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03853109","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-2693","authenticated-orcid":false,"given":"Timothy","family":"Price","sequence":"first","affiliation":[{"name":"The Queen Elizabeth Hospital, Woodville, Adelaide, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Lugowska","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie Institute of Oncology Warsaw, Warszawa, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sant P","family":"Chawla","sequence":"additional","affiliation":[{"name":"Sarcoma Oncology Center, Santa Monica, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Falchook","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute at HealthONE, Denver, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Centre, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose G","family":"Monzon","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik-Tobias","family":"Arkenau","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute and Cancer Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mun","family":"Hui","sequence":"additional","affiliation":[{"name":"Chris O\u2019Brien Lifehouse, Camperdown, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3675-953X","authenticated-orcid":false,"given":"Yasutoshi","family":"Kuboki","sequence":"additional","affiliation":[{"name":"National Cancer Center-Hospital East, Kashiwa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafal","family":"Dziadziuszko","sequence":"additional","affiliation":[{"name":"Medical University of Gdansk, Gdansk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Shibaki","sequence":"additional","affiliation":[{"name":"Wakayama Medical University, Wakayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3490-2195","authenticated-orcid":false,"given":"Min Hee","family":"Hong","sequence":"additional","affiliation":[{"name":"Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Tan","sequence":"additional","affiliation":[{"name":"National Cancer Centre Singapore, SingHealth, and Duke-NUS Medical School, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caio Max","family":"Rocha Lima","sequence":"additional","affiliation":[{"name":"Wake Forest University Baptist Health, Winston-Salem, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kejia","family":"Wang","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antreas","family":"Hindoyan","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibing","family":"Shi","sequence":"additional","affiliation":[{"name":"Amgen Inc San Francisco, South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansen","family":"Wong","sequence":"additional","affiliation":[{"name":"Amgen Inc San Francisco, South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira","family":"Kistler","sequence":"additional","affiliation":[{"name":"Amgen Inc San Francisco, South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Prenen","sequence":"additional","affiliation":[{"name":"University Hospital Antwerp, Edegem, Antwerp, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"2025102702544155000_15.5.e088578.1","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci Adv"},{"key":"2025102702544155000_15.5.e088578.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"2025102702544155000_15.5.e088578.3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"2025102702544155000_15.5.e088578.4","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405"},{"key":"2025102702544155000_15.5.e088578.5","doi-asserted-by":"publisher","DOI":"10.1002\/med.21765"},{"key":"2025102702544155000_15.5.e088578.6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"2025102702544155000_15.5.e088578.7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000453","article-title":"Phase IA\/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors","volume":"8","author":"Desai","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025102702544155000_15.5.e088578.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2609"},{"key":"2025102702544155000_15.5.e088578.9","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J"},{"key":"2025102702544155000_15.5.e088578.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13770","article-title":"Safety, antitumor activity, and pharmacokinetics of toripalimab, a programmed cell death 1 inhibitor, in patients with advanced non-small cell lung cancer: A phase 1 trial","volume":"3","author":"Wang","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025102702544155000_15.5.e088578.11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cac2.12068","article-title":"A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors","volume":"40","author":"Wei","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"2025102702544155000_15.5.e088578.12","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28408-3","article-title":"Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)","volume":"13","author":"Xu","year":"2022","journal-title":"Nat Commun"},{"key":"2025102702544155000_15.5.e088578.13","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"2025102702544155000_15.5.e088578.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"2025102702544155000_15.5.e088578.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9"},{"key":"2025102702544155000_15.5.e088578.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017"},{"key":"2025102702544155000_15.5.e088578.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.08.004"},{"key":"2025102702544155000_15.5.e088578.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.027"},{"key":"2025102702544155000_15.5.e088578.19","doi-asserted-by":"publisher","DOI":"10.1177\/1740774510382799"},{"key":"2025102702544155000_15.5.e088578.20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00280-020-04161-6","article-title":"Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies","volume":"87","author":"Kitano","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025102702544155000_15.5.e088578.21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10637-016-0411-2","article-title":"Phase I study of nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors","volume":"35","author":"Yamamoto","year":"2017","journal-title":"Invest New Drugs"},{"key":"2025102702544155000_15.5.e088578.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"2025102702544155000_15.5.e088578.23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2607"},{"key":"2025102702544155000_15.5.e088578.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699"},{"key":"2025102702544155000_15.5.e088578.25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw174"},{"key":"2025102702544155000_15.5.e088578.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2842"},{"key":"2025102702544155000_15.5.e088578.27","doi-asserted-by":"crossref","first-page":"109638","DOI":"10.1016\/j.intimp.2022.109638","article-title":"Advances in pharmacokinetics and pharmacodynamics of PD-1\/PD-L1 inhibitors","volume":"115","author":"Yan","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2025102702544155000_15.5.e088578.28","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009337512"},{"key":"2025102702544155000_15.5.e088578.29","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0586-0","article-title":"Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics","volume":"7","author":"Davda","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025102702544155000_15.5.e088578.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.08.026"},{"key":"2025102702544155000_15.5.e088578.31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2021.02.034","article-title":"Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort","volume":"155","author":"Moreno","year":"2021","journal-title":"Lung Cancer (Auckl)"},{"key":"2025102702544155000_15.5.e088578.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01743-4"},{"key":"2025102702544155000_15.5.e088578.33","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","author":"Yi","year":"2018","journal-title":"Mol Cancer"},{"key":"2025102702544155000_15.5.e088578.34","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jamaoncol.2019.2311","article-title":"Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1","volume":"5","author":"Lee","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025102702544155000_15.5.e088578.35","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490"},{"key":"2025102702544155000_15.5.e088578.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5"},{"key":"2025102702544155000_15.5.e088578.37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2025102702544155000_15.5.e088578.38","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature New Biol"},{"key":"2025102702544155000_15.5.e088578.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00561-4"},{"key":"2025102702544155000_15.5.e088578.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444."},{"key":"2025102702544155000_15.5.e088578.41","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"2025102702544155000_15.5.e088578.42","doi-asserted-by":"crossref","first-page":"v477","DOI":"10.1093\/annonc\/mdz253.018","article-title":"Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158","volume":"30","author":"Marabelle","year":"2019","journal-title":"Ann Oncol"},{"key":"2025102702544155000_15.5.e088578.43","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10120-022-01308-7","article-title":"The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric\/gastroesophageal junction adenocarcinoma","volume":"25","author":"Lu","year":"2022","journal-title":"Gastric Cancer"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-088578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:54:49Z","timestamp":1761558889000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-088578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,2]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bmjopen-2024-088578"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088578","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}